A Scandinavian clinical trial has revealed that low-dose aspirin can halve the risk of colon and rectal cancer recurrence in patients with specific genetic mutations. The research, involving over 3,500 patients, is the first randomized study to confirm aspirin’s powerful effect in this context. The findings suggest aspirin could become a widely available, inexpensive precision medicine, reshaping cancer treatment strategies globally.
from Top Health News -- ScienceDaily https://ift.tt/0PAeEbi
No comments:
Post a Comment